文献速递脊柱关节炎

戈利木单抗治疗活动性非放射学轴性脊柱关节炎的长期耐受性和疗效:开放标签扩展研究结果

Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

GO-AHEAD研究的开放标签扩展(OLE)评估戈利木单抗(GLM)治疗非放射学轴性脊柱关节炎(nr-axSpA)的长期疗效与安全性。198例随机患者中189例进入OLE,GLM/GLM组与PBO/GLM组从第16周到第52周应答比例均增加,但GLM/GLM组始终更高。OLE期间GLM/GLM组不良事件总体发生率低于PBO/GLM组,GLM耐受性良好并带来长期获益。

要点

  • GLM/GLM组ASAS20应答从71.1%升至83.9%,PBO/GLM组从40.0%升至75.0%。
  • GLM/GLM组ASAS40应答从56.7%升至76.3%,PBO/GLM组从23.0%升至59.4%。
  • OLE期间GLM/GLM组不良事件总体发生率41.9%,低于PBO/GLM组的54.2%。

核心结论

  • nr-axSpA患者接受GLM治疗第52周时临床疗效持续改善,GLM耐受性良好并提供显著长期获益。

研究设计与样本

  • GO-AHEAD研究的开放标签扩展(OLE),双盲期GLM组和安慰剂(PBO)组均接受GLM 50 mg每4周一次,OLE治疗36周并额外8周安全性随访。
  • 198例随机患者中189/198(95.5%)进入OLE,174/198(87.9%)完成所有访视,所有进入OLE并接受至少1剂研究治疗的患者纳入疗效和安全性分析。

主要发现

  • 从第16周到第52周,GLM/GLM组和PBO/GLM组的应答者比例均增加,但GLM/GLM组在整个OLE期间始终高于PBO/GLM组。
  • ASAS20应答:GLM/GLM组71.1%至83.9%,PBO/GLM组40.0%至75.0%。
  • ASAS40应答:GLM/GLM组56.7%至76.3%,PBO/GLM组23.0%至59.4%。
  • ASAS部分缓解:GLM/GLM组33.0%至53.8%,PBO/GLM组18.0%至45.8%。
  • OLE期间不良事件总体发生率GLM/GLM组为41.9%,PBO/GLM组为54.2%。

关键数值与推荐

  • 主要疗效评估为达到ASAS20和ASAS40改善标准的患者比例,应答者分析采用无应答者填补法。

临床怎么用

  • 对于活动性nr-axSpA患者,GLM 50 mg每4周一次治疗至第52周可带来持续改善的ASAS20、ASAS40和ASAS部分缓解应答。
  • 长期使用GLM时需关注不良事件,OLE期间GLM/GLM组不良事件总体发生率低于PBO/GLM组。

局限性

  • 原文未报告OLE研究的盲法设置、安慰剂对照时长及具体不良事件类型等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We report the open-label extension (OLE) of the GO-AHEAD study evaluating the long-term efficacy and safety of golimumab (GLM) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). METHODS: Patients [both GLM- and placebo (PBO)-treated in the double-blind phase] received GLM 50 mg every 4 weeks during the OLE (36-week treatment; additional 8-week safety follow-up; GLM/GLM and PBO/GLM groups). All patients who entered and received ≥1 dose of study treatment in the OLE were included in the efficacy and safety analyses. The primary efficacy evaluations were the proportions of patients achieving 20% and 40% improvement in the ASAS criteria (ASAS20 and ASAS40, respectively). Responders' analyses were calculated using a non-responder imputation approach. RESULTS: Of 198 patients randomised, 189/198 (95.5%) entered the OLE; 174/198 patients (87.9%) completed all visits. Although the proportion of responders increased from week 16 to week 52 in the OLE in both GLM/GLM and PBO/GLM groups, the GLM/GLM group had a higher proportion of responders than the PBO/GLM group throughout the OLE from week 16 to week 52 (ASAS20: 71.1% to 83.9% vs 40.0% to 75.0%, respectively; ASAS40: 56.7% to 76.3% vs 23.0% to 59.4%, respectively; ASAS partial remission: 33.0% to 53.8% and 18.0% to 45.8%). In the OLE, the overall incidence of AEs was lower in the GLM/GLM vs PBO/GLM groups (41.9% and 54.2%). CONCLUSIONS: Sustained improvement in clinical efficacy was observed at 52 weeks in patients with nr-axSpA following GLM treatment. GLM was well tolerated and provided substantial long-term benefits to patients with nr-axSpA. TRIAL REGISTRATION: NCT01453725; United States National Library of Medicine clinical trials database; www.clinicaltrials.gov.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. van der Heijde D, Dougados M, Maksymowych WP, et al. Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension. Rheumatology (Oxford). 2022. PMID: 33878154. doi:10.1093/rheumatology/keab346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。